Antimicrobial resistance (AMR) is a growing public health threat that has been identified as a top priority by the World Health Organization (WHO). AMR refers to the ability of bacteria, viruses, fungi and parasites to resist the effects of antimicrobial drugs, which makes it difficult to treat infections and causes increased morbidity, mortality and healthcare costs.
In recent years, the pharmaceutical industry has been at the forefront of efforts to combat AMR, investing significant resources into research and development of new drugs to combat resistant infections. However, the problem of AMR is complex and multifaceted, requiring a coordinated effort from all stakeholders including policymakers, healthcare providers, researchers, and the public.
The development and use of antibiotics in both humans and animals has contributed significantly to the emergence of AMR. The overuse and misuse of antibiotics, such as prescribing antibiotics for viral infections, incomplete treatment courses, and widespread use of antibiotics in animal feed, has led to the development of resistant strains of bacteria.
To combat AMR, the pharmaceutical industry is focusing on researching and developing new antibiotics and alternative therapies such as bacteriophages, monoclonal antibodies, and probiotics. The WHO has identified a number of priority pathogens for which new antibiotics are urgently needed, including Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae.
In addition, the pharmaceutical industry is also focusing on improving the stewardship of existing antibiotics, promoting responsible use, and reducing the development of resistance. This can be achieved through strategies such as developing combination therapies, optimizing dosages, and promoting education and awareness among healthcare professionals and the general public.
Collaboration and partnerships are also critical in the fight against AMR, bringing together stakeholders from different sectors to share knowledge and resources. The pharmaceutical industry is working with governments, academia, and non-governmental organizations to accelerate the development of new therapies and promote responsible use of antibiotics.
In conclusion, antimicrobial resistance is a significant public health issue that requires a collaborative effort from all stakeholders. The pharmaceutical industry is committed to researching and developing new therapies to combat resistant infections, promoting responsible use of antibiotics, and collaborating with other stakeholders to tackle this global health threat. By working together, we can help to preserve our most valuable antimicrobial agents and ensure that antibiotics continue to be effective for generations to come.
Below is a list of articles about AMR from the European Pharmaceutical Manufacturer magazine.